Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
PG Richardson, C Mitsiades, I Ghobrial… - Current opinion in …, 2006 - journals.lww.com
PG Richardson, C Mitsiades, I Ghobrial, K Anderson
Current opinion in oncology, 2006•journals.lww.comBortezomib-based combinations show promising activity in relapsed or refractory multiple
myeloma, including reversal of chemoresistance to previously used agents. As high
complete and overall response rates translate into longer survival, bortezomib-based
combinations appear likely to have a significant impact on the multiple myeloma treatment
algorithm and on the course of the disease itself.
myeloma, including reversal of chemoresistance to previously used agents. As high
complete and overall response rates translate into longer survival, bortezomib-based
combinations appear likely to have a significant impact on the multiple myeloma treatment
algorithm and on the course of the disease itself.
Summary
Bortezomib-based combinations show promising activity in relapsed or refractory multiple myeloma, including reversal of chemoresistance to previously used agents. As high complete and overall response rates translate into longer survival, bortezomib-based combinations appear likely to have a significant impact on the multiple myeloma treatment algorithm and on the course of the disease itself.
Lippincott Williams & Wilkins
以上显示的是最相近的搜索结果。 查看全部搜索结果